Last updated: August 9, 2026
Levorphanol tartrate is a mature, low-volume Schedule II opioid with limited commercial visibility in the United States. Its original brand, Levo-Dromoran, is no longer a meaningful commercial driver, while generic levorphanol tartrate remains available through a small supplier base. The product has no material remaining composition-of-matter patent protection, no biosimilar exposure, and limited opportunity for premium pricing. Its financial profile is driven by scarcity, manufacturing continuity, controlled-substance compliance, and institutional demand rather than market expansion.
What is levorphanol tartrate used for?
Levorphanol tartrate is an opioid analgesic indicated for the management of moderate to severe pain when an opioid analgesic is appropriate. It is administered orally in tablet form and is pharmacologically distinct from many commonly used opioids because it has both mu-opioid receptor activity and clinically relevant NMDA-receptor antagonist and norepinephrine reuptake effects.
The U.S. product is generally supplied as 2 mg and 3 mg tablets. Levorphanol tartrate is the salt form used for oral pharmaceutical formulations. It is a racemic compound related to the morphinan class, while levorphanol is the levorotatory active opioid component.[1]
| Attribute |
Levorphanol tartrate |
| Therapeutic class |
Opioid analgesic |
| Primary use |
Moderate to severe pain |
| U.S. controlled-substance status |
Schedule II |
| Common dosage forms |
Oral tablets |
| Common strengths |
2 mg and 3 mg |
| Original brand |
Levo-Dromoran |
| Current commercial model |
Generic, low-volume prescription product |
| Biosimilar relevance |
None |
| Primary commercial constraint |
Controlled-substance manufacturing and limited demand |
Levorphanol is not a first-line product for broad outpatient pain treatment. Prescribing is concentrated in patients requiring an alternative opioid, patients with opioid tolerance, and selected cases involving neuropathic or complex pain.
How large is the levorphanol tartrate market?
The U.S. levorphanol tartrate market is small compared with markets for oxycodone, hydrocodone, morphine, hydromorphone, fentanyl, and buprenorphine. Public company filings generally do not report levorphanol revenue separately. Claims databases and commercial prescription datasets may contain product-level utilization, but those data are not normally disclosed in issuer filings.
The market has several structural characteristics:
- Low prescription volume relative to mainstream opioid analgesics.
- Limited manufacturer participation.
- Generic pricing rather than brand pricing.
- Periodic availability concerns when a supplier exits or reduces production.
- Demand concentrated in specialist and institutional settings.
- High regulatory overhead relative to annual sales.
Levorphanol therefore has a niche-market economic profile. A manufacturer can obtain favorable pricing during periods of constrained supply, but the absolute revenue pool remains limited.
What drives levorphanol tartrate demand?
Demand is shaped by clinical substitution and supply availability rather than population growth. The principal demand drivers are:
- Patients who require an opioid with a longer duration of action than some short-acting alternatives.
- Patients with opioid tolerance or prior exposure to other opioids.
- Physicians seeking an alternative because of adverse effects, inadequate analgesia, or difficult opioid rotation.
- Specialist use in pain medicine, palliative care, and selected oncology settings.
- Institutional protocols that retain levorphanol as an alternative analgesic.
Demand is constrained by the product's narrow clinical familiarity, opioid-prescribing controls, conversion complexity, and the availability of cheaper or more familiar alternatives.
What companies manufacture or market levorphanol tartrate?
The U.S. market has historically included generic suppliers operating through abbreviated new drug applications. Product availability has changed over time as companies entered or discontinued their products.
Public regulatory labeling has identified generic levorphanol tartrate products associated with manufacturers including Hikma Pharmaceuticals and legacy U.S. generic manufacturers. The exact active supplier roster can change because controlled-substance products may be discontinued, transferred, or temporarily unavailable without creating a broad public market announcement.[2]
| Commercial layer |
Market characteristic |
| Brand originator |
Levo-Dromoran was the historical reference product |
| Generic manufacturers |
Small number of approved or marketed suppliers |
| Wholesalers |
Standard pharmaceutical distribution channels |
| End users |
Retail pharmacies, hospitals, pain clinics, and hospice providers |
| Pricing power |
Higher than a fully commoditized generic during shortages, but limited by low demand |
| Switching risk |
High because prescribers can use other opioid analgesics |
A small supplier base can support intermittent price increases. It also creates volume risk: if a manufacturer leaves the market, remaining suppliers may face higher demand but also increased regulatory and production requirements.
What is the FDA regulatory status of levorphanol tartrate?
Levorphanol tartrate is an FDA-approved prescription opioid analgesic. The product is regulated as a Schedule II controlled substance under the Controlled Substances Act.[3]
The FDA label includes warnings applicable to opioid analgesics, including respiratory depression, misuse, abuse, addiction, overdose, neonatal opioid withdrawal, and risks associated with concomitant central nervous system depressants.[1]
What is the Orange Book status of levorphanol tartrate?
Levorphanol tartrate is a legacy small-molecule product with generic competition. Its commercial protection is not based on active brand exclusivity or a recent innovative-drug exclusivity period.
The key Orange Book implications are:
- The product is eligible for abbreviated approval pathways.
- Any listed patents associated with the original product are old relative to the current generic market.
- There is no relevant biologic exclusivity period.
- No current patent barrier is known to prevent generic competition.
- A Paragraph IV dispute would be commercially unlikely unless a new formulation or method-of-use patent were introduced.
The original drug's practical market protection ended decades ago. Current commercial performance depends on manufacturing economics and distribution, not patent exclusivity.
What patents protect levorphanol tartrate?
The original levorphanol tartrate molecule and conventional oral tablet technology are not protected by commercially meaningful, unexpired U.S. composition-of-matter patents. The product was introduced in the mid-20th century, placing any original patent rights well beyond their ordinary term.[4]
| Patent category |
Current commercial relevance |
| Original compound patent |
Expired |
| Original salt or conventional tablet claims |
Expired or no longer commercially blocking |
| Generic product patents |
No known material barrier to ordinary generic entry |
| Extended-release formulation patents |
Potentially relevant only if a new product is developed |
| Method-of-use patents |
Possible for a new clinical indication, but no established blocking estate is apparent |
| Manufacturing patents |
Could protect a process, but would not prevent use of alternative processes |
The patent opportunity is therefore defensive or incremental. A new company would need to differentiate the product through formulation, delivery, dosing, manufacturing efficiency, or a narrowly defined clinical use. A conventional levorphanol tartrate tablet would have little basis for durable patent exclusivity.
When did levorphanol tartrate lose exclusivity?
Levorphanol tartrate lost effective exclusivity long before the modern generic-drug era. The original brand, Levo-Dromoran, was introduced decades ago, and the product's active ingredient is now available through generic labeling and abbreviated-approval pathways.
No current reference-product exclusivity period is commercially relevant. Pediatric exclusivity, new chemical entity exclusivity, and modern orphan-drug exclusivity do not provide a meaningful market barrier for the established product.
Are there Paragraph IV challenges involving levorphanol tartrate?
No high-profile, current Paragraph IV litigation is associated with conventional levorphanol tartrate tablets in the public record. That outcome is commercially logical. A Paragraph IV challenge is generally relevant when an applicant seeks approval against unexpired listed patents. Levorphanol's conventional product does not present a major active patent estate.
Future litigation risk would arise mainly from:
- A newly developed extended-release product.
- Abuse-deterrent or tamper-resistant technology.
- A transdermal, subcutaneous, or other non-oral delivery system.
- A patent covering a specific opioid-rotation method.
- A formulation claiming improved pharmacokinetics or reduced adverse effects.
Those claims would protect a new product, not the established levorphanol tartrate tablet as a whole.
What formulations are protected or commercially differentiated?
The established commercial product is an immediate-release oral tablet. It has limited formulation differentiation.
Potentially protectable product concepts include:
Extended-release levorphanol
An extended-release tablet could reduce dosing frequency and create a product-specific patent estate. It would face regulatory and clinical-development burdens because opioid formulations require abuse-risk assessment, dose-conversion controls, and careful labeling.
Abuse-deterrent formulation
An abuse-deterrent formulation could obtain formulation patents and potentially support premium pricing. The commercial opportunity would depend on whether payers and prescribers recognize a benefit over existing generic opioids.
Non-oral delivery
Transdermal, buccal, sublingual, injectable, or implantable delivery could create stronger differentiation. These products would require new development programs and would not be interchangeable with standard oral levorphanol tartrate without regulatory approval.
Combination products
A combination with another analgesic or adjuvant could support method-of-use or formulation claims. The product would face additional safety and dosing complexity.
No evidence establishes that these next-generation concepts currently generate a material commercial market for levorphanol.
How strong is the levorphanol tartrate patent estate?
The patent estate for standard levorphanol tartrate is weak from an exclusivity perspective. It may be described as technically mature, legally open, and commercially dependent on execution.
| Patent-strength factor |
Assessment |
| Compound protection |
None of practical relevance |
| Conventional tablet protection |
None of practical relevance |
| Generic-entry barrier |
Low |
| Formulation white space |
Available for new delivery systems |
| Method-of-use opportunity |
Narrow and evidence-dependent |
| Manufacturing barrier |
Moderate because of controlled-substance requirements |
| Litigation protection |
Low |
| Regulatory moat |
Moderate |
| Supply-chain moat |
Potentially meaningful in a constrained market |
The most durable barrier is operational rather than legal. A supplier with an established DEA quota, validated manufacturing process, stable active-pharmaceutical-ingredient sourcing, and dependable wholesaler relationships may outperform patent-rich competitors that lack reliable production.
What generic entry risks exist for levorphanol tartrate?
Generic entry risk is already realized because levorphanol is a mature generic product. The more relevant risk is additional supplier entry.
Additional entrants could:
- Reduce prices.
- Improve pharmacy availability.
- Increase substitution away from incumbent suppliers.
- Pressure contract and wholesale pricing.
- Reduce the value of temporary shortage premiums.
At the same time, the small market may limit new entry. A manufacturer must support controlled-substance compliance, pharmacovigilance, quality systems, inventory controls, and distribution requirements even when annual unit demand is modest.
The market can therefore be open legally but unattractive economically.
What patent litigation and settlement agreements affect levorphanol tartrate?
No material current patent litigation or major settlement agreement is publicly associated with the conventional levorphanol tartrate tablet market. There is no known branded patent settlement shaping generic launch timing.
A future dispute would most likely involve a reformulated product rather than the legacy tablet. Relevant claims could concern release profiles, abuse deterrence, dosage conversion, or a specific treatment protocol.
How does levorphanol compare with competing opioid analgesics?
Levorphanol competes against established generic opioids on clinical familiarity, availability, price, and dosing convenience.
| Product |
Relative market position |
Main competitive advantage over levorphanol |
| Morphine |
Broad institutional use |
Familiarity, low cost, extensive dosage forms |
| Hydromorphone |
Strong hospital and specialty use |
Predictable parenteral and oral options |
| Oxycodone |
Large outpatient market |
Prescriber familiarity and broad distribution |
| Methadone |
Complex pain and opioid-use treatment |
Multiple indications and low unit cost |
| Fentanyl |
Severe pain and procedural use |
Potent delivery systems and established institutional demand |
| Buprenorphine |
Pain and opioid-use disorder |
Safety profile in selected settings and broader treatment role |
| Levorphanol |
Niche analgesic |
Alternative pharmacology and specialist utility |
Levorphanol's differentiation is pharmacological rather than commercial. It does not have the scale, distribution, or formulation breadth of the major generic opioid products.
What is the financial trajectory for levorphanol tartrate?
The financial trajectory is best characterized as flat to volatile at the product level, with limited long-term growth. Standalone revenue figures are generally not reported by public manufacturers, and the product is too small to materially affect diversified pharmaceutical company results.
Revenue profile
Levorphanol revenue is likely determined by:
- Low baseline prescription volume.
- Generic price erosion during normal supply conditions.
- Temporary price expansion during shortages.
- Supplier withdrawals or allocation.
- Contracting with hospitals and specialty distributors.
- Product discontinuation risk.
The product can generate attractive gross margins for a low-cost generic manufacturer during periods of constrained supply. That opportunity is difficult to scale because the total addressable market is small.
Cost structure
Major cost components include:
- Controlled-substance API procurement.
- DEA registration and quota management.
- Manufacturing validation.
- Quality-control testing.
- Serialization and supply-chain controls.
- Pharmacovigilance and opioid-risk compliance.
- Inventory carrying costs.
- Distribution and wholesaler fees.
Manufacturing cost per tablet is unlikely to be the main economic issue. Fixed compliance and supply-chain costs have greater importance because they are spread across a limited volume base.
Investment profile
For an established generic manufacturer, levorphanol may be a useful niche product that improves portfolio breadth. For a new entrant, the investment case is weaker unless the company has:
- Existing controlled-substance infrastructure.
- A reliable API source.
- A distribution platform.
- A strategy for shortage-prone products.
- A differentiated formulation under development.
The product is unlikely to support a standalone commercial company or a major licensing transaction in its conventional form.
What geographic markets offer opportunity?
The United States is the most visible regulated market because of its established labeling, generic pathway, and controlled-substance infrastructure. International opportunity is limited by differing opioid policies, reimbursement systems, prescribing practices, and product approvals.
Potential markets require country-specific analysis of:
- National marketing authorization.
- Controlled-drug scheduling.
- Import quotas.
- Opioid-prescribing restrictions.
- Reimbursement.
- Local generic substitution rules.
- API and finished-dose manufacturing requirements.
A company cannot assume that U.S. generic approval translates into international market access. In many jurisdictions, levorphanol has limited clinical recognition and may not be routinely stocked.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate. The molecule itself is old and technically accessible, but controlled-substance production creates additional operational requirements.
Key barriers include:
- Procurement of qualified levorphanol API.
- Controlled-substance quota allocation.
- Secure storage and chain-of-custody systems.
- Batch-release testing.
- Stability data for the tartrate salt and tablet.
- Reliable packaging and serialization.
- Forecasting a low-volume product without excessive inventory.
- Maintaining commercial supply during demand spikes.
These barriers can create an effective supply moat even when patent barriers are absent. They also increase discontinuation risk if a manufacturer cannot justify ongoing compliance costs.
Key Takeaways
- Levorphanol tartrate is a mature Schedule II opioid analgesic with a small U.S. generic market.
- The original Levo-Dromoran brand no longer provides meaningful commercial protection.
- Standard levorphanol tartrate tablets have no material remaining composition-of-matter patent barrier.
- Current market economics depend on supplier concentration, controlled-substance compliance, and availability.
- Public companies generally do not disclose standalone levorphanol revenue.
- The product has limited growth potential but can generate niche margins during supply constraints.
- Conventional generic entry risk is already realized; future competitive threats would come from additional suppliers or differentiated formulations.
- The strongest commercial opportunity lies in operational execution or a new delivery system, not in ordinary immediate-release tablets.
- No major current Paragraph IV litigation or settlement agreement is associated with the legacy product.
- Biosimilar risk is irrelevant because levorphanol tartrate is a small-molecule drug.
Frequently Asked Questions
Is levorphanol tartrate still commercially available?
Yes. Generic levorphanol tartrate has been marketed in the United States, although availability can vary by supplier, wholesaler, pharmacy, and controlled-substance inventory conditions.
Does levorphanol tartrate have an active U.S. patent?
No commercially meaningful patent barrier is associated with the conventional levorphanol tartrate tablet. Any new formulation could create separate patent rights.
Is levorphanol tartrate a high-revenue pharmaceutical product?
No. It is a low-volume niche generic, and manufacturers generally do not report it as a separate revenue category.
Can a company obtain premium pricing for levorphanol tartrate?
Temporary premium pricing is possible when supply is constrained. Long-term premium pricing is difficult because the product is generic and physicians can substitute other opioid analgesics.
Is levorphanol tartrate a candidate for a licensing deal?
The conventional tablet is a weak licensing asset. A differentiated extended-release, abuse-deterrent, or non-oral formulation would have stronger licensing potential but would require new clinical, regulatory, and manufacturing investment.
References
- DailyMed. (n.d.). Levorphanol tartrate tablet: U.S. prescribing information. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA and FDA-approved drug labeling for levorphanol tartrate.
- U.S. Drug Enforcement Administration. (2024). Controlled substances act and drug scheduling information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
